Consistent with this, Zhu and colleagues found that lenalidomide-adapted MM cell lines lacking CRBN abnormalities showed impaired IRF4 downregulation and upregulation of IL-6/STAT3 signaling [9]. This evidence concerns the gene CRBN and Miyoshi myopathy.